Brown Adipocyte Reprogramming via Gene Introduction

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods for generating brown adipocytes for treating obesity and related metabolic disorders are inefficient and pose risks due to low UCP1 expression and oncogenesis concerns.

Innovation Solution

A method involving the introduction of specific genes such as PRDM16, C/EBPβ, Myc family genes, GLIS family genes, Klf family genes, Oct family genes, Sox family genes, and Lin-28 into somatic cells to efficiently produce brown adipocytes with high UCP1 expression, effectively differentiating them into brown adipocyte-like cells.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If brown adipocytes are derived from iPS cells via mesenchymal stem cells, then brown adipocytes can be generated, but the process requires a long time and poses oncogenesis risks

Engineering Contradiction:

Improvesafety from oncogenesisVSAvoiddifferentiation time

Core Design Contradiction:

ReliabilityVSLoss of time

Solution Approach 1:

The patent extracts and eliminates the intermediate mesenchymal stem cell stage from the differentiation pathway, directly converting somatic cells into brown adipocytes through genetic reprogramming. This removes the time-consuming and oncogenic intermediate step while maintaining the desired brown adipocyte output.

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The patent introduces reprogramming genes (such as Oct4, Sox2, Klf4, c-Myc) into somatic cells before the differentiation process to enable direct conversion into brown adipocytes. This preliminary genetic modification bypasses the need for time-consuming intermediate stages and reduces oncogenesis risks by establishing the correct cellular identity early.

Inventive Principle:

Principle #10Preliminary action

2Manufacturing precision

If PRDM16 and C/EBPβ genes are introduced into myoblasts or fibroblasts, then brown adipocyte-like cells are differentiated, but UCP1 expression is very low

Engineering Contradiction:

ImproveUCP1 expression levelVSAvoiddifferentiation efficiency

Core Design Contradiction:

Manufacturing precisionVSEase of manufacture

Solution Approach 1:

The patent changes the genetic parameters by introducing additional reprogramming genes (Oct4, Sox2, Klf4, c-Myc) beyond the basic PRDM16 and C/EBPβ combination. This genetic parameter enhancement significantly boosts UCP1 expression and improves brown adipocyte characteristics while maintaining differentiation efficiency.

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent creates a composite genetic system combining multiple genes (PRDM16, C/EBPβ, Oct4, Sox2, Klf4, c-Myc) that work synergistically to produce high UCP1 expression. This composite approach leverages the strengths of each gene to achieve superior brown adipocyte differentiation compared to individual or simple gene combinations.

Inventive Principle:

Principle #40Composite materials

3Reliability

If conventional methods are used to generate brown adipocytes, then the process is simple, but UCP1 expression is insufficient for effective treatment

Engineering Contradiction:

Improvetherapeutic effectivenessVSAvoidgene introduction complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent applies local quality enhancement by introducing specific reprogramming genes (Oct4, Sox2, Klf4, c-Myc) at strategic points in the differentiation pathway. This targeted genetic modification ensures high UCP1 expression and therapeutic effectiveness in the final brown adipocytes while maintaining overall process simplicity.

Inventive Principle:

Principle #3Local quality

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The method generates brown adipocytes with excellent properties, effectively treating obesity, diabetes, and metabolic syndrome by enhancing UCP1 expression and reducing visceral and subcutaneous fat, while minimizing oncogenesis risks.

Implementation Method 1

A method for preparing a brown adipocyte from a somatic cell of a mammal by introducing at least one brown adipocyte-related gene or expression product thereof and at least one reprogramming-related gene or expression product thereof into the somatic cell

Methodology Applied

Scientific EffectGene expression and cellular differentiation:

Implementation Method 2

This is because uncoupling protein 1 (UCP1), a mitochondrial inner membrane protein specifically expressed in BAs, uncouples oxidative phosphorylation

Methodology Applied

Scientific EffectUncoupling protein 1 (UCP1) mechanism:

Implementation Method 3

uncouples oxidative phosphorylation

Methodology Applied

Scientific EffectOxidative phosphorylation:

Data Source

PatentUS20200399603A1Brown fat cells and method for preparing same

Publication Date: 2020.12.24 KYOTO PREFECTURAL PUBLIC UNIV CORP

AI summary

This invention provides a method for preparing a brown adipocyte from a somatic cell of a mammal by introducing at least one brown adipocyte-related gene or expression product thereof and at least one reprogramming-related gene or expression product thereof into the somatic cell, the brown adipocyte-related gene being at least one member selected from the group consisting of PRDM16(P) and C/EBPβ(C), the reprogramming-related gene being at least one member selected from the group consisting of Myc family genes (c-Myc(M), N-Myc, L-Myc(L), S-Myc, and B-Myc), GLIS family genes (GLIS1 (G), GLIS 2, and GLIS 3), Klf family genes (KLF1, KLF2, KLF3, KLF4(K), KLF5, KLF6, KLF7, KLF8, KLF9, KLF10, KLF11, KLF12, KLF13, KLF14, KLF15, KLF16, and KLF17), Oct family genes, Sox family genes, and Lin-28.